圣湘生物 (688289.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.5x

Market Cap

CNY 8.63B

MomentumView details →

1D Return

−5.58%

YTD Return

—

RSI (14)

52.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.5x

Market Cap

CNY 8.63B

RSI (14)

52.9

MomentumView details →

1D Return

−5.58%

YTD Return

—

ProfitabilityView details →

Gross Margin

74.84%

Net Margin

9.79%

EBITDA Margin

26.60%

ROE (TTM)

2.19%

ROA (TTM)

1.63%

Asset Turnover

0.17x

GrowthView details →

Revenue YoY

+3.94%

EPS YoY

−46.51%

FCF YoY

—

Revenue CAGR 3Y

−36.63%

EPS CAGR 3Y

−53.17%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

4.26x

Quick Ratio

3.90x

Div Yield

3.27%

Div Rate

CNY 0.52

Div Growth 1Y

−51.40%

Financials snapshotView financials →

Revenue (TTM)

1.60B

Net Income (TTM)

156.94M

Op. CF (TTM)

216.81M

Next earningsOct 28, 2026 →

Latest newsMore news →

Sansure Biotech proposed a cash dividend of 2.65 yuan per 10 shares (tax inclusive), totaling 151 million yuan, subject to shareholder approval.9d ago

Sansure Biotech announced its first-half 2026 results: revenue of 834 million yuan, down 3.95% year-on-year; net profit attributable to shareholders of 98.0173 million yuan, down 39.76%; non-recurring net profit of 53.7043 million yuan, down 60.48%.9d ago

Similar companies

AptarGroup, Inc.ATR Masimo CorporationMASI Repligen CorporationRGEN 爱博医疗688050.SH Kaisa Health Group Holdings Limited00876.HK Modern Dental Group Limited03600.HK Find similar companies →

Latest newsMore news →

Sansure Biotech proposed a cash dividend of 2.65 yuan per 10 shares (tax inclusive), totaling 151 million yuan, subject to shareholder approval.9d ago Sansure Biotech announced its first-half 2026 results: revenue of 834 million yuan, down 3.95% year-on-year; net profit attributable to shareholders of 98.0173 million yuan, down 39.76%; non-recurring net profit of 53.7043 million yuan, down 60.48%.9d ago